No Clinically Significant Drug Interactions Between PrEP and This Medication Regimen
There are no clinically significant drug interactions between tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV PrEP and the patient's current medications: lisdexamfetamine (Vyvanse), dexamfetamine, levothyroxine, testosterone enanthate, and clonidine. You can safely prescribe PrEP to this patient.
Key Interaction Considerations
Renal Function Monitoring
The primary concern with TDF/FTC relates to renal excretion pathways, not interactions with this patient's medications 1. The FDA label specifies that drugs eliminated by active tubular secretion (such as acyclovir, ganciclovir, aminoglycosides, and high-dose NSAIDs) may increase tenofovir concentrations 1. None of the patient's current medications fall into this category.
Monitor baseline and ongoing renal function (serum creatinine and estimated creatinine clearance) as recommended prior to PrEP initiation and at least every 6 months during therapy 2. This is standard PrEP monitoring, not specific to these medications.
Testosterone Enanthate Considerations
Recent pharmacokinetic studies demonstrate no clinically relevant interaction between testosterone therapy and TDF/FTC 3, 4. Specifically:
- Masculinizing hormone therapy does not affect tenofovir concentrations
- May cause a minor increase in emtricitabine levels that is not clinically significant
- TDF/FTC does not alter testosterone levels 3
PrEP efficacy is maintained in transgender men and others receiving testosterone therapy 3, 4.
Stimulant Medications (Vyvanse, Dexamfetamine)
Amphetamines are metabolized primarily through hepatic pathways and renal excretion, but do not compete with TDF/FTC for renal tubular secretion 1. No pharmacokinetic interaction is expected or documented.
Levothyroxine and Clonidine
These medications have no known interactions with TDF/FTC. Levothyroxine absorption occurs in the small intestine and is not affected by TDF/FTC. Clonidine is metabolized hepatically and excreted renally but does not interact with nucleoside reverse transcriptase inhibitors 1.
Standard PrEP Initiation Protocol
Follow the 2020 IAS-USA guidelines 2:
Pre-Initiation Testing Required
- Combined HIV antibody/antigen test (within 7 days)
- Serum creatinine and estimated creatinine clearance
- Hepatitis B surface antigen
- Hepatitis C antibody
- STI screening (gonorrhea, chlamydia, syphilis)
Dosing Recommendations
- For MSM: Double dose (2 tablets) on day 1, then once daily; continue 2 days after last exposure if discontinuing 2
- For others: Once daily; continue 7 days after last exposure if discontinuing 2
Ongoing Monitoring
- HIV testing every 3 months
- Creatinine assessment every 6 months (more frequently if age >50 years or on medications affecting blood pressure/glucose) 5, 2
- STI screening every 3 months
Common Pitfalls to Avoid
- Do not delay PrEP due to unfounded concerns about drug interactions with these medications
- Do not require medication adjustments for the patient's current regimen
- Do not assume testosterone therapy affects PrEP efficacy—the evidence shows it does not 3, 4
- Monitor adherence closely, as this is the primary determinant of PrEP effectiveness, not drug interactions 6
The patient can safely initiate PrEP while continuing all current medications without dose adjustments.